Biopharma leader with two exits. Extensive scientific knowledge in AI, Genomics, oncology, Neuroscience, Rare diseases drug discovery and development spanning from small molecule to cell therapy. Successful track record of private and public investor relations, global strategic planning, corporate strategy, revenue growth, various business development sourcing and transactions, buy&sell side diligence, alliance management, scientific project management, leadership through transformational change. PhD in Genomics.

Founder and CEO of a stealth biotechnology company, leveraging artificial intelligence to drive more efficient experimentation. Her career has spanned investing and operating roles in both hypergrowth and mature companies. She brings a unique breadth of experience, having served as a hands-on executive leading multiple strategic functions across industries, particularly technology and life sciences. She currently advises companies across both the public and private sectors. Previously, Anna Marie was on the executive team at Ginkgo Bioworks (NYSE:DNA), where over the years she built and led numerous functions including finance, corporate development, and AI.

Co-founder and General Partner at Formation Venture Engineering funds and FVE Foundry. He previously served as the founding CEO of Sage Science, Thrive Bioscience, and Owl Scientific (now ThermoFisher). FVE Foundry and its related VE Funds are focused on life science startups with game-changing technology platforms. FVE’s portfolio includes Akston Biosciences, NeuroDex, Cell IDx (acquired by Danaher), LeviSense Medical, Adeptrix, NonExomics and Twilight Biosciences. Gary is an advisor and board member of several life science companies, including Asymmetrex and Vakston. He guides strategy, builds positive synergistic mission-critical relationships, and raises capital for companies with world-worthy technologies and teams.

Dr. Rothenhaus is former SVP and Chief Medical Officer of Athenahealth. He is a nationally recognized expert on the use of information technology in support of emerging delivery models and the provision of safe and effective patient-centered care. Dr. Rothenhaus has served on a several national health information technology committees. He has authored over 30 publications, and has participated in the development of a number of health care IT standards.

Zach has over fifteen years of investment management industry experience, spent in fiduciary service to the world's largest institutional investors. Before founding Alpha Due Diligence, he held senior roles on the Portfolio Management, Investment Analytics, and Trading teams at Arrowstreet Capital, LP, a leading quantitative asset management firm. Zach holds a BA from Oberlin College with a double major in Mathematics and Economics.

Richard C. Friedberg, MD, PhD, MHCM, FCAP is an award-winning Senior Executive with 30+ years of worldwide success in medicine, academics, biotechnology, and diagnostics. His direct experience in health care delivery, compliance, strategic planning, and risk mitigation includes key leadership positions throughout his career in diverse private, public, and academic sectors.

Experienced Anesthesiologist with executive and leadership roles within the hospital & health care industry. Dr. Bailin is a skilled clinician and expert anesthesiologist, providing medical and business insights, clinical and strategic support to entities ranging from device developers, pharmaceutical companies, physician practices and individual physicians. He has extensive experience as an anesthesiologist at Massachusetts General Hospital in Boston. Michael has held leadership positions within several academic and private hospitals and boards and graduated from MIT and Harvard Medical School.